Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ticarcillin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.62 |
| ▸ | RECQL | P46063 | 4/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | TEK | Q02763 | 1/20 | 0.62 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | RARB | P10826 | 1/20 | 0.60 |
| ▸ | RARG | P13631 | 1/20 | 0.60 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.60 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.60 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ticarcillin SCHEMBL10738085 | 1.00 | PTGS1 (1.00) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL34025 | 1.00 | PTGS1 (1.00) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL5047437 | 1.00 | PTGS1 (1.00) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL28757995 | 0.99 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL9929365 | 0.99 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL193733 | 0.99 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL4935398 | 0.99 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL4228859 | 0.99 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL4935408 | 0.99 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL27742456 | 0.99 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0074783-B1 | BETA-LACTAMASE INHIBITING 2-BETA-SUBSTITUTED-2-ALPHA-METHYL-(5R) PENAM-3-ALPHA-CARBOXYLIC ACID 1,1-DIOXIDES AND INTERMEDIATES THEREFOR | PFIZER INC. (US) | 1985-07-31 | — | — | EP | claimed |
| EP-0083977-A1 | 6-Alpha-hydroxymethylpenicillanic acid sulfone as a beta-lactamase inhibitor | PFIZER INC. (US) | 1983-07-20 | — | — | EP | claimed |
| EP-0074783-A1 | Beta-lactamase inhibiting 2-beta-substituted-2-alpha-methyl-(5R) penam-3-alpha-carboxylic acid 1,1-dioxides and intermediates therefor | PFIZER INC. (US) | 1983-03-23 | — | — | EP | claimed |
| EP-0008917-B1 | PENAM-3-CARBOXYLIC ACID 1,1-DIOXIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | PFIZER INC. (US) | 1982-11-24 | — | — | EP | claimed |
| US-4287181-A | TO ENHANCE THE EFFECTIVENESS OF B-LACTAM ANTIBIOTICS | PFIZER INC. (US) | 1981-09-01 | — | — | US | claimed |
| US-4256733-A | Acetoxymethyl penam compounds as β-lactamase inhibitors | PFIZER INC. (US) | 1981-03-17 | — | — | US | claimed |
| EP-0008917-A1 | Penam-3-carboxylic acid 1,1-dioxides, process for their preparation and pharmaceutical compositions | PFIZER INC. (US) | 1980-03-19 | — | — | EP | claimed |
| WO-2018182515-A1 | METHODS OF MODIFYING FUNGI AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-10-04 | — | — | WO | disclosed |
| US-9084735-B2 | Self-assembling bis-urea compounds for drug delivery | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2015-07-21 | — | — | US | disclosed |
| US-20150037390-A1 | SELF-ASSEMBLING BIS-UREA COMPOUNDS FOR DRUG DELIVERY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-02-05 | — | — | US | disclosed |
| US-4656263-A | 6-β-substituted penicillanic acid compound free of the 6-α-epimer | PFIZER INC. (US) | 1987-04-07 | — | — | US | disclosed |
| EP-0095341-B1 | PENICILLANIC ACID DIOXIDE PRODRUG | PFIZER INC. (US) | 1986-02-26 | — | — | EP | disclosed |
| EP-0074783-B1 | BETA-LACTAMASE INHIBITING 2-BETA-SUBSTITUTED-2-ALPHA-METHYL-(5R) PENAM-3-ALPHA-CARBOXYLIC ACID 1,1-DIOXIDES AND INTERMEDIATES THEREFOR | PFIZER INC. (US) | 1985-07-31 | — | — | EP | disclosed |
| US-4323499-A | 6-(2-Aryl-2-(1,1-dioxopenicillanoyloxy-methoxycarbonyl)acetamido penicillanic acids | PFIZER INC. (US) | 1982-04-06 | — | — | US | disclosed |
| US-4287181-A | TO ENHANCE THE EFFECTIVENESS OF B-LACTAM ANTIBIOTICS | PFIZER INC. (US) | 1981-09-01 | — | — | US | disclosed |
| US-4256733-A | Acetoxymethyl penam compounds as β-lactamase inhibitors | PFIZER INC. (US) | 1981-03-17 | — | — | US | disclosed |
| US-4241050-A | Penam 1,1-dioxides as beta-lactamase inhibitors | PFIZER INC. (US) | 1980-12-23 | — | — | US | disclosed |
| US-4234579-A | Penicillanic acid 1,1-dioxides as β-lactamase inhibitors | PFIZER INC. (US) | 1980-11-18 | — | — | US | disclosed |
| EP-0008917-A1 | Penam-3-carboxylic acid 1,1-dioxides, process for their preparation and pharmaceutical compositions | PFIZER INC. (US) | 1980-03-19 | — | — | EP | disclosed |
| US-4066664-A | Intermediates for preparing α-carboxy-α-(3-thienyl)penicillin and cephalosporin derivatives | RECHERCHE ET INDUSTRIE THERAPEUTIQUES (BE) | 1978-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150037390-A1 | SELF-ASSEMBLING BIS-UREA COMPOUNDS FOR DRUG DELIVERY | SLC14A1, NONO, PUF60 | PTGS1 4023/4885SMN1; SMN2 1675/4885KDM4E 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.